Drug Trial Radar · NCT06546670
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
161
Planned (sponsor's estimate)
Start
Aug 15, 2024
Primary completion
May 1, 2028
Study completion May 27, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
Conditions
- Sickle Cell Disease
Interventions
ITU512Drug
ITU512 is an investigational, oral, low molecular weight (LMW) compound.
PlaceboDrug
An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEsTime frame: Up to approximately 60 days
- Part 1A, Part 1B , Part 1C: Dose discontinued due to AETime frame: Up to 30 days
- Part 2A, Part 2B: Incidence of AEs and SAEsTime frame: Up to 5 months
- Part 2A, Part 2B: Dose interruptions and reductionsTime frame: Up to 4 months
- Part 2A, Part 2B: Dose intensityTime frame: Up to 4 months
- Part 2B: Fetal hemoglobin (HbF)%Time frame: Month 4
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama · Recruiting
Quotient Sciences Sea View
Miami, Florida · Completed
Boston Childrens Hospital
Boston, Massachusetts · Recruiting
Icahn School Of Med At Mount Sinai
New York, New York · Recruiting
Levine Cancer Insitute Carolinas Healthcare System
Charlotte, North Carolina · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Lifespan
Providence, Rhode Island · Recruiting
UT Health Science Center
Houston, Texas · Recruiting
Novartis Investigative Site
São Paulo, Brazil · Recruiting
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting
Novartis Investigative Site
Adana, Yuregir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.